These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 18469809)

  • 1. A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity.
    Montagnoli A; Valsasina B; Croci V; Menichincheri M; Rainoldi S; Marchesi V; Tibolla M; Tenca P; Brotherton D; Albanese C; Patton V; Alzani R; Ciavolella A; Sola F; Molinari A; Volpi D; Avanzi N; Fiorentini F; Cattoni M; Healy S; Ballinari D; Pesenti E; Isacchi A; Moll J; Bensimon A; Vanotti E; Santocanale C
    Nat Chem Biol; 2008 Jun; 4(6):357-65. PubMed ID: 18469809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stopping replication, at the beginning.
    Jackson PK
    Nat Chem Biol; 2008 Jun; 4(6):331-2. PubMed ID: 18488006
    [No Abstract]   [Full Text] [Related]  

  • 3. Cdc7 as a potential new target for cancer therapy.
    Ito S; Taniyami C; Arai N; Masai H
    Drug News Perspect; 2008 Nov; 21(9):481-8. PubMed ID: 19180266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cdc7 kinase inhibitors: pyrrolopyridinones as potential antitumor agents. 1. Synthesis and structure-activity relationships.
    Vanotti E; Amici R; Bargiotti A; Berthelsen J; Bosotti R; Ciavolella A; Cirla A; Cristiani C; D'Alessio R; Forte B; Isacchi A; Martina K; Menichincheri M; Molinari A; Montagnoli A; Orsini P; Pillan A; Roletto F; Scolaro A; Tibolla M; Valsasina B; Varasi M; Volpi D; Santocanale C
    J Med Chem; 2008 Feb; 51(3):487-501. PubMed ID: 18201066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First Cdc7 kinase inhibitors: pyrrolopyridinones as potent and orally active antitumor agents. 2. Lead discovery.
    Menichincheri M; Bargiotti A; Berthelsen J; Bertrand JA; Bossi R; Ciavolella A; Cirla A; Cristiani C; Croci V; D'Alessio R; Fasolini M; Fiorentini F; Forte B; Isacchi A; Martina K; Molinari A; Montagnoli A; Orsini P; Orzi F; Pesenti E; Pezzetta D; Pillan A; Poggesi I; Roletto F; Scolaro A; Tatò M; Tibolla M; Valsasina B; Varasi M; Volpi D; Santocanale C; Vanotti E
    J Med Chem; 2009 Jan; 52(2):293-307. PubMed ID: 19115845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting cell division cycle 7 kinase: a new approach for cancer therapy.
    Montagnoli A; Moll J; Colotta F
    Clin Cancer Res; 2010 Sep; 16(18):4503-8. PubMed ID: 20647475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cdc7 kinase inhibitors: 5-heteroaryl-3-carboxamido-2-aryl pyrroles as potential antitumor agents. 1. Lead finding.
    Menichincheri M; Albanese C; Alli C; Ballinari D; Bargiotti A; Caldarelli M; Ciavolella A; Cirla A; Colombo M; Colotta F; Croci V; D'Alessio R; D'Anello M; Ermoli A; Fiorentini F; Forte B; Galvani A; Giordano P; Isacchi A; Martina K; Molinari A; Moll JK; Montagnoli A; Orsini P; Orzi F; Pesenti E; Pillan A; Roletto F; Scolaro A; Tatò M; Tibolla M; Valsasina B; Varasi M; Vianello P; Volpi D; Santocanale C; Vanotti E
    J Med Chem; 2010 Oct; 53(20):7296-315. PubMed ID: 20873740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cdc7 inhibition reveals a p53-dependent replication checkpoint that is defective in cancer cells.
    Montagnoli A; Tenca P; Sola F; Carpani D; Brotherton D; Albanese C; Santocanale C
    Cancer Res; 2004 Oct; 64(19):7110-6. PubMed ID: 15466207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA Replication Dynamics and Cellular Responses to ATP Competitive CDC7 Kinase Inhibitors.
    Rainey MD; Quachthithu H; Gaboriau D; Santocanale C
    ACS Chem Biol; 2017 Jul; 12(7):1893-1902. PubMed ID: 28560864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and evaluation of pyrido-thieno-pyrimidines as potent and selective Cdc7 kinase inhibitors.
    Zhao C; Tovar C; Yin X; Xu Q; Todorov IT; Vassilev LT; Chen L
    Bioorg Med Chem Lett; 2009 Jan; 19(2):319-23. PubMed ID: 19071019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PHA-680632, a novel Aurora kinase inhibitor with potent antitumoral activity.
    Soncini C; Carpinelli P; Gianellini L; Fancelli D; Vianello P; Rusconi L; Storici P; Zugnoni P; Pesenti E; Croci V; Ceruti R; Giorgini ML; Cappella P; Ballinari D; Sola F; Varasi M; Bravo R; Moll J
    Clin Cancer Res; 2006 Jul; 12(13):4080-9. PubMed ID: 16818708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of action of a dual Cdc7/Cdk9 kinase inhibitor against quiescent and proliferating CLL cells.
    Natoni A; Murillo LS; Kliszczak AE; Catherwood MA; Montagnoli A; Samali A; O'Dwyer M; Santocanale C
    Mol Cancer Ther; 2011 Sep; 10(9):1624-34. PubMed ID: 21768328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The potent Cdc7-Dbf4 (DDK) kinase inhibitor XL413 has limited activity in many cancer cell lines and discovery of potential new DDK inhibitor scaffolds.
    Sasi NK; Tiwari K; Soon FF; Bonte D; Wang T; Melcher K; Xu HE; Weinreich M
    PLoS One; 2014; 9(11):e113300. PubMed ID: 25412417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell division cycle 7 kinase inhibitors: 1H-pyrrolo[2,3-b]pyridines, synthesis and structure-activity relationships.
    Ermoli A; Bargiotti A; Brasca MG; Ciavolella A; Colombo N; Fachin G; Isacchi A; Menichincheri M; Molinari A; Montagnoli A; Pillan A; Rainoldi S; Sirtori FR; Sola F; Thieffine S; Tibolla M; Valsasina B; Volpi D; Santocanale C; Vanotti E
    J Med Chem; 2009 Jul; 52(14):4380-90. PubMed ID: 19555113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimization of a dihydropyrrolopyrazole series of transforming growth factor-beta type I receptor kinase domain inhibitors: discovery of an orally bioavailable transforming growth factor-beta receptor type I inhibitor as antitumor agent.
    Li HY; McMillen WT; Heap CR; McCann DJ; Yan L; Campbell RM; Mundla SR; King CH; Dierks EA; Anderson BD; Britt KS; Huss KL; Voss MD; Wang Y; Clawson DK; Yingling JM; Sawyer JS
    J Med Chem; 2008 Apr; 51(7):2302-6. PubMed ID: 18314943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and structure-activity relationship of trisubstituted thiazoles as Cdc7 kinase inhibitors.
    Reichelt A; Bailis JM; Bartberger MD; Yao G; Shu H; Kaller MR; Allen JG; Weidner MF; Keegan KS; Dao JH
    Eur J Med Chem; 2014 Jun; 80():364-82. PubMed ID: 24793884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of Novel Cdc7 Kinase Inhibitors as Anti-Cancer Agents that Target the Interaction with Dbf4 by the Fragment Complementation and Drug Repositioning Approach.
    Cheng AN; Lo YK; Lin YS; Tang TK; Hsu CH; Hsu JT; Lee AY
    EBioMedicine; 2018 Oct; 36():241-251. PubMed ID: 30293817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of XL413, a potent and selective CDC7 inhibitor.
    Koltun ES; Tsuhako AL; Brown DS; Aay N; Arcalas A; Chan V; Du H; Engst S; Ferguson K; Franzini M; Galan A; Holst CR; Huang P; Kane B; Kim MH; Li J; Markby D; Mohan M; Noson K; Plonowski A; Richards SJ; Robertson S; Shaw K; Stott G; Stout TJ; Young J; Yu P; Zaharia CA; Zhang W; Zhou P; Nuss JM; Xu W; Kearney PC
    Bioorg Med Chem Lett; 2012 Jun; 22(11):3727-31. PubMed ID: 22560567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual Inhibition of Cdc7 and Cdk9 by PHA-767491 Suppresses Hepatocarcinoma Synergistically with 5-Fluorouracil.
    Li W; Zhao XL; Shang SQ; Shen HQ; Chen X
    Curr Cancer Drug Targets; 2015; 15(3):196-204. PubMed ID: 25643258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imidazopyridine derivatives as potent and selective Polo-like kinase (PLK) inhibitors.
    Sato Y; Onozaki Y; Sugimoto T; Kurihara H; Kamijo K; Kadowaki C; Tsujino T; Watanabe A; Otsuki S; Mitsuya M; Iida M; Haze K; Machida T; Nakatsuru Y; Komatani H; Kotani H; Iwasawa Y
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4673-8. PubMed ID: 19589677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.